Bath & Body Works' (BBWI) "Neutral" Rating Reiterated at JPMorgan Chase & Co.

Key Points

• JPMorgan Chase & Co. has reaffirmed a "neutral" rating for Bath & Body Works (BBWI) with a price objective of $26.00, indicating a potential upside of 0.51% from its current price.
• Other investment firms have varied opinions, with Citigroup lowering its price target from $42.00 to $40.00 while Telsey Advisory Group maintained an "outperform" rating with a $38.00 price objective.
• The company's latest earnings report showed $1.55 billion in revenue for the quarter, matching analysts' estimates, but reflecting a 0.8% decrease from the same quarter the previous year.

Bath & Body Works (NYSE:BBWI - Get Free Report)'s stock had its "neutral" rating reaffirmed by stock analysts at JPMorgan Chase & Co. in a report issued on Monday,Benzinga reports. They currently have a $26.00 price objective on the stock. JPMorgan Chase & Co.'s price target indicates a potential upside of 0.51% from the stock's current price.

BBWI has been the subject of several other research reports. Citigroup decreased their price target on shares of Bath & Body Works from $42.00 to $40.00 and set a "buy" rating for the company in a report on Tuesday, August 19th. Barclays boosted their price target on shares of Bath & Body Works from $30.00 to $32.00 and gave the company an "equal weight" rating in a report on Friday, August 29th. Telsey Advisory Group reaffirmed an "outperform" rating and issued a $38.00 price objective on shares of Bath & Body Works in a research report on Thursday, August 28th. Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Bath & Body Works in a research report on Saturday, September 27th. Finally, Wall Street Zen cut shares of Bath & Body Works from a "buy" rating to a "hold" rating in a research report on Saturday, August 9th. Eleven investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $38.15.

Bath & Body Works Price Performance

Shares of Bath & Body Works stock opened at $25.87 on Monday. The firm has a 50 day simple moving average of $28.42 and a 200 day simple moving average of $29.46. Bath & Body Works has a fifty-two week low of $24.93 and a fifty-two week high of $41.87. The firm has a market cap of $5.33 billion, a P/E ratio of 7.68, a P/E/G ratio of 0.88 and a beta of 1.52.

Bath & Body Works (NYSE:BBWI - Get Free Report) last released its earnings results on Thursday, August 28th. The company reported $0.37 EPS for the quarter, hitting analysts' consensus estimates of $0.37. Bath & Body Works had a net margin of 9.88% and a negative return on equity of 48.43%. The firm had revenue of $1.55 billion during the quarter, compared to analyst estimates of $1.55 billion. During the same quarter in the previous year, the business earned $0.37 EPS. The business's quarterly revenue was down .8% compared to the same quarter last year. Bath & Body Works has set its Q3 2025 guidance at 0.370-0.45 EPS. FY 2025 guidance at 3.350-3.600 EPS. On average, sell-side analysts expect that Bath & Body Works will post 3.3 EPS for the current year.

Institutional Investors Weigh In On Bath & Body Works

Institutional investors and hedge funds have recently modified their holdings of the company. Stonehage Fleming Financial Services Holdings Ltd bought a new stake in shares of Bath & Body Works in the 2nd quarter valued at about $33,000. SVB Wealth LLC acquired a new position in Bath & Body Works in the 1st quarter valued at about $35,000. Geneos Wealth Management Inc. grew its stake in Bath & Body Works by 217.7% in the 1st quarter. Geneos Wealth Management Inc. now owns 1,169 shares of the company's stock valued at $35,000 after buying an additional 801 shares during the last quarter. Parallel Advisors LLC grew its stake in Bath & Body Works by 63.3% in the 2nd quarter. Parallel Advisors LLC now owns 1,241 shares of the company's stock valued at $37,000 after buying an additional 481 shares during the last quarter. Finally, Golden State Wealth Management LLC grew its stake in Bath & Body Works by 94.7% in the 1st quarter. Golden State Wealth Management LLC now owns 1,320 shares of the company's stock valued at $40,000 after buying an additional 642 shares during the last quarter. 95.14% of the stock is owned by institutional investors.

About Bath & Body Works

Bath & Body Works, Inc is a specialty retailers and home to America's Favorite Fragrances, offering a breadth of exclusive fragrances for the body and home, including the selling collections for fine fragrance mist, body lotion and body cream, 3-wick candles, home fragrance diffusers and liquid hand soap.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.